{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T05:43:05Z","timestamp":1770356585362,"version":"3.49.0"},"reference-count":85,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Chest Medicine"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1016\/j.ccm.2009.02.007","type":"journal-article","created":{"date-parts":[[2009,4,17]],"date-time":"2009-04-17T04:38:50Z","timestamp":1239943130000},"page":"279-286","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Invasive Fungal Infections in the Era of Biologics"],"prefix":"10.1016","volume":"30","author":[{"given":"Tamra M.","family":"Arnold","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine R.","family":"Sears","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chadi A.","family":"Hage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccm.2009.02.007_bib1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/ncprheum0438","article-title":"Drug insight: different mechanisms of action of tumor necrosis factor antagonists\u2014passive-aggressive behavior?","volume":"3","author":"Rigby","year":"2007","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.ccm.2009.02.007_bib2","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1002\/art.10583","article-title":"Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept","volume":"46","author":"Lee","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ccm.2009.02.007_bib3","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ccm.2009.02.007_bib4","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.2146\/ajhp050514","article-title":"Treatment of rheumatoid arthritis","volume":"63","author":"Gaffo","year":"2006","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.ccm.2009.02.007_bib5","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.2165\/00003495-200464120-00001","article-title":"Biological agents for rheumatoid arthritis: targeting both physical function and structural damage","volume":"64","author":"Klinkhoff","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.ccm.2009.02.007_bib6","series-title":"Remicade: [package insert]","year":"2008"},{"key":"10.1016\/j.ccm.2009.02.007_bib7","series-title":"Etanercept [package insert]","year":"2008"},{"key":"10.1016\/j.ccm.2009.02.007_bib8","series-title":"Humira [package insert]","year":"2008"},{"issue":"Suppl 3","key":"10.1016\/j.ccm.2009.02.007_bib9","doi-asserted-by":"crossref","first-page":"S189","DOI":"10.1086\/429994","article-title":"Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis","volume":"41","author":"Algood","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.ccm.2009.02.007_bib10","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1128\/IAI.69.3.1847-1855.2001","article-title":"Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology","volume":"69","author":"Mohan","year":"2001","journal-title":"Infect Immun"},{"issue":"9","key":"10.1016\/j.ccm.2009.02.007_bib11","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1164\/rccm.200206-563OC","article-title":"Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy","volume":"167","author":"Wood","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.ccm.2009.02.007_bib12","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1086\/498981","article-title":"T cells require tumor necrosis factor-alpha to provide protective immunity in mice infected with Histoplasma capsulatum","volume":"193","author":"Deepe","year":"2006","journal-title":"J\u00a0Infect Dis"},{"issue":"Suppl 3","key":"10.1016\/j.ccm.2009.02.007_bib13","doi-asserted-by":"crossref","first-page":"S208","DOI":"10.1086\/430000","article-title":"Tumor necrosis factor inhibition and invasive fungal infections","volume":"41","author":"Filler","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"9194","key":"10.1016\/j.ccm.2009.02.007_bib14","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ccm.2009.02.007_bib15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1572-0241.2005.40647.x","article-title":"Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab","volume":"100","author":"Papadakis","year":"2005","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.ccm.2009.02.007_bib16","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s00384-004-0645-x","article-title":"Effectiveness and tolerability of repeated treatment with infliximab in patients with Crohn's disease: a retrospective data analysis in Germany","volume":"20","author":"Witthoft","year":"2005","journal-title":"Int J Colorectal Dis"},{"issue":"9","key":"10.1016\/j.ccm.2009.02.007_bib17","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1002\/art.10529","article-title":"Predictors of infection in rheumatoid arthritis","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.ccm.2009.02.007_bib18","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/rheumatology\/kel236","article-title":"Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients","volume":"46","author":"Salliot","year":"2007","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.ccm.2009.02.007_bib19","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1086\/587989","article-title":"Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network","volume":"46","author":"Winthrop","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ccm.2009.02.007_bib20","doi-asserted-by":"crossref","first-page":"594","DOI":"10.7326\/0003-4819-149-8-200810210-00020","article-title":"Disseminated histoplasmosis associated with the treatment of rheumatoid arthritis with anticytokine therapy","volume":"149","author":"Asrani","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ccm.2009.02.007_bib21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","article-title":"The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients","volume":"126","author":"Colombel","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ccm.2009.02.007_bib22","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/ncpgasthep1119","article-title":"Infliximab-induced disseminated histoplasmosis in a patient with Crohn's disease","volume":"5","author":"Galandiuk","year":"2008","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"10.1016\/j.ccm.2009.02.007_bib23","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1056\/NEJMcps041569","article-title":"Clinical problem-solving. The unturned stone","volume":"352","author":"Goulet","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ccm.2009.02.007_bib24","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.rmed.2005.09.020","article-title":"Reactivation histoplasmosis after treatment with anti-tumor necrosis factor alpha in a patient from a nonendemic area","volume":"100","author":"Jain","year":"2006","journal-title":"Respir Med"},{"key":"10.1016\/j.ccm.2009.02.007_bib25","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S0002-9343(01)00945-7","article-title":"Reactivation of histoplasmosis after treatment with infliximab","volume":"112","author":"Nakelchik","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.ccm.2009.02.007_bib26","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/01.rhu.0000083606.71931.79","article-title":"Panniculitis: a presenting manifestation of disseminated histoplasmosis in a patient with rheumatoid arthritis","volume":"9","author":"Sawalha","year":"2003","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.ccm.2009.02.007_bib27","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1136\/ard.2005.043166","article-title":"Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis","volume":"65","author":"Schiff","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ccm.2009.02.007_bib28","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists","volume":"38","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ccm.2009.02.007_bib29","unstructured":"Zaman R, Abbas M. Case report of fatal disseminated histoplasmosis in a patient with rheumatoid arthritis following therapy with etanercept and methotrexate Presented at the 40th annual meeting of the Infectious Diseases Society of America; Chicago, October 24\u201327, 2002 [abstract 378]."},{"key":"10.1016\/j.ccm.2009.02.007_bib30","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1056\/NEJM200202213460815","article-title":"Tuberculosis and treatment with infliximab","volume":"346","author":"Zhang","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ccm.2009.02.007_bib31","unstructured":"Food and Drug Administration. FDA alert; information for healthcare professionals; Cimzia (certolizumab pegol), Enbrel (etanercept), Humira (adalimumab), and Remicade (infliximab). Available at: http:\/\/www.fda.gov\/cder\/drug\/InfoSheets\/HCP\/TNF_blockersHCP.htm Accessed December 30, 2008."},{"key":"10.1016\/j.ccm.2009.02.007_bib32","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0025-6196(11)60839-2","article-title":"Fungal infections complicating tumor necrosis factor alpha blockade therapy","volume":"83","author":"Tsiodras","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ccm.2009.02.007_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/art.20454","article-title":"Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists","volume":"50","author":"Bergstrom","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ccm.2009.02.007_bib34","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/01.smj.0000242797.49218.44","article-title":"Coccidioidomycosis pneumonia in a nonendemic area associated with infliximab","volume":"100","author":"Dweik","year":"2007","journal-title":"South Med J"},{"key":"10.1016\/j.ccm.2009.02.007_bib35","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/art.20159","article-title":"Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate","volume":"50","author":"Maini","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ccm.2009.02.007_bib36","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1196\/annals.1406.027","article-title":"Coccidioidomycosis in rheumatology patients: incidence and potential risk factors","volume":"1111","author":"Mertz","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ccm.2009.02.007_bib37","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1752-1947-1-79","article-title":"Fatal miliary coccidioidomycosis in a patient receiving infliximab therapy: a case report","volume":"1","author":"Rogan","year":"2007","journal-title":"J Med Case Reports"},{"key":"10.1016\/j.ccm.2009.02.007_bib38","unstructured":"Ruderman E, Markenson J. Granulomatous infections and tumor necrosis factor antagonist therapies. Presented at the Proceedings of the Annual European Congress of Rheumatology EULAR; Lisbon, Portugal, June 19\u201321, 2003 [abstract THU0209]."},{"key":"10.1016\/j.ccm.2009.02.007_bib39","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/ajh.20752","article-title":"Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation","volume":"82","author":"Busca","year":"2007","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ccm.2009.02.007_bib40","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/blood-2003-12-4241","article-title":"Tumor necrosis factor-alpha blockade for the treatment of acute GVHD","volume":"104","author":"Couriel","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ccm.2009.02.007_bib41","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1086\/502250","article-title":"Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: a possible healthcare-associated case?","volume":"24","author":"De Rosa","year":"2003","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.ccm.2009.02.007_bib42","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1365-2559.2006.02488.x","article-title":"Angioinvasive aspergillosis presenting as neutropenic colitis","volume":"49","author":"Finn","year":"2006","journal-title":"Histopathology"},{"key":"10.1016\/j.ccm.2009.02.007_bib43","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/ajh.10392","article-title":"Infliximab for steroid-refractory acute GVHD: a case series","volume":"74","author":"Jacobsohn","year":"2003","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ccm.2009.02.007_bib44","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1023\/B:DDAS.0000042246.58984.98","article-title":"Pneumocystis carinii pneumonia with oral candidiasis after infliximab therapy for Crohn's disease","volume":"49","author":"Kaur","year":"2004","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.ccm.2009.02.007_bib45","first-page":"267","article-title":"Pulmonary aspergillosis in a patient with rheumatoid arthritis treated by etanercept","volume":"22","author":"Lassoued","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ccm.2009.02.007_bib46","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1182\/blood-2003-01-0267","article-title":"Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study","volume":"102","author":"Marty","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ccm.2009.02.007_bib47","first-page":"1352","article-title":"Infliximab treatment for steroid-refractory acute graft-versus-host disease","volume":"89","author":"Patriarca","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.ccm.2009.02.007_bib48","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/rheumatology\/ken088","article-title":"Central nervous system Aspergillus fumigatus presenting as cranial nerve palsy in a patient with ankylosing spondylitis on anti-TNF therapy","volume":"47","author":"Slusher","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ccm.2009.02.007_bib49","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1007\/s00134-003-1867-z","article-title":"Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate","volume":"29","author":"van der Klooster","year":"2003","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ccm.2009.02.007_bib50","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJM200104053441415","article-title":"Invasive pulmonary aspergillosis associated with infliximab therapy","volume":"344","author":"Warris","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ccm.2009.02.007_bib51","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1007\/s10620-006-9455-z","article-title":"Mucormycosis presenting as recurrent gastric perforation in a patient with Crohn's disease on glucocorticoid, 6-mercaptopurine, and infliximab therapy","volume":"52","author":"Devlin","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.ccm.2009.02.007_bib52","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1442-9071.2007.01458.x","article-title":"Disseminated mucormycosis and orbital ischaemia in combination immunosuppression with a tumour necrosis factor alpha inhibitor","volume":"35","author":"Singh","year":"2007","journal-title":"Clin Experiment Ophthalmol"},{"key":"10.1016\/j.ccm.2009.02.007_bib53","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0210-5705(03)70477-4","volume":"27","author":"Belda","year":"2004","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.ccm.2009.02.007_bib54","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/ard.2006.066761","article-title":"Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial","volume":"66","author":"Burmester","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ccm.2009.02.007_bib55","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1002\/art.11151","article-title":"Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and toll-like receptor 4 expression","volume":"48","author":"Netea","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ccm.2009.02.007_bib56","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1572-0241.2001.03612.x","article-title":"Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients","volume":"96","author":"Ricart","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ccm.2009.02.007_bib57","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1007\/s10096-004-1185-6","article-title":"Cavitating pneumonia after treatment with infliximab and prednisone","volume":"23","author":"Arend","year":"2004","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ccm.2009.02.007_bib58","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0213-005X(06)73780-6","volume":"24","author":"Chavez-Lopez","year":"2006","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.ccm.2009.02.007_bib59","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1378\/chest.124.6.2395","article-title":"Pulmonary cryptococcosis after initiation of anti-tumor necrosis factor-alpha therapy","volume":"124","author":"Hage","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.ccm.2009.02.007_bib60","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1525-1470.2007.00404.x","article-title":"Localized cutaneous Cryptococcus albidus infection in a 14-year-old boy on etanercept therapy","volume":"24","author":"Hoang","year":"2007","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.ccm.2009.02.007_bib61","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3201\/eid1306.070154","article-title":"Invasive cryptococcosis and adalimumab treatment","volume":"13","author":"Horcajada","year":"2007","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.ccm.2009.02.007_bib62","first-page":"606","article-title":"Pneumonia due to Cryptococcus neoformans in a patient receiving infliximab: possible zoonotic transmission from a pet cockatiel","volume":"49","author":"Shrestha","year":"2004","journal-title":"Respir Care"},{"key":"10.1016\/j.ccm.2009.02.007_bib63","unstructured":"Starrett W, Czachor J, Dallal M, et\u00a0al. Cryptococcal pneumonia following treatment with infliximab for rheumatoid arthritis. Presented at the 40th annual meeting of the Infectious Diseases Society of America; Chicago, October 24\u201327, 2002 [abstract 374:110]."},{"key":"10.1016\/j.ccm.2009.02.007_bib64","first-page":"1561","article-title":"Disseminated cryptococcal infection in rheumatoid arthritis treated with methotrexate and infliximab","volume":"29","author":"True","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ccm.2009.02.007_bib65","unstructured":"Rituximab: (Rituxin) [package insert]. San Francisco (CA): Genentech, Inc.; 2008."},{"key":"10.1016\/j.ccm.2009.02.007_bib66","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.idc.2006.09.001","article-title":"Impact of biologic agents on infectious diseases","volume":"20","author":"Saketkoo","year":"2006","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.ccm.2009.02.007_bib67","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1097\/INF.0b013e31815a044f","article-title":"Monoclonal antibody therapeutics and risk for infection","volume":"26","author":"Gea-Banacloche","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ccm.2009.02.007_bib68","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2007.083188","article-title":"Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ccm.2009.02.007_bib69","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s12185-008-0066-7","article-title":"Increased incidence of interstitial pneumonia by CHOP combined with rituximab","volume":"87","author":"Ennishi","year":"2008","journal-title":"Int J Hematol"},{"key":"10.1016\/j.ccm.2009.02.007_bib70","unstructured":"Hatoum HH, Sarosi GA, Knox KS, et\u00a0al. Acute respiratory failure and diffuse pulmonary infiltrates four weeks after rituximab therapy. Respiratory Medicine CME, in press."},{"key":"10.1016\/j.ccm.2009.02.007_bib71","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3324\/haematol.10564","article-title":"Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen","volume":"92","author":"Kolstad","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.ccm.2009.02.007_bib72","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/blood-2004-08-3300","article-title":"Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials","volume":"105","author":"Spina","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ccm.2009.02.007_bib73","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1093\/rheumatology\/ken234","article-title":"Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis","volume":"47","author":"Teichmann","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ccm.2009.02.007_bib74","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1600-0609.2007.00994.x","article-title":"Three cases of Pneumocystis jirovecii pneumonia (PCP) during first-line treatment with rituximab in combination with CHOP-14 for aggressive B-cell non-Hodgkin's lymphoma","volume":"80","author":"Venhuizen","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ccm.2009.02.007_bib75","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/00007890-200201150-00019","article-title":"Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication","volume":"73","author":"Verschuuren","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.ccm.2009.02.007_bib76","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00277-006-0206-1","article-title":"Severe infectious complications in a patient treated with rituximab for idiopathic thrombocytopenic purpura","volume":"86","author":"Fianchi","year":"2007","journal-title":"Ann Hematol"},{"issue":"Suppl:ECR33","key":"10.1016\/j.ccm.2009.02.007_bib77","article-title":"Successful treatment of pure red cell aplasia with repeated, low doses of rituximab in two patients after ABO-incompatible allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia","volume":"90","author":"Helbig","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.ccm.2009.02.007_bib78","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1093\/rheumatology\/ken143","article-title":"Efficacy and safety of rituximab in a patient with active rheumatoid arthritis and chronic disseminated pulmonary aspergillosis and history of tuberculosis","volume":"47","author":"Jung","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ccm.2009.02.007_bib79","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/01.TP.0000112934.12622.2B","article-title":"Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics","volume":"77","author":"Vieira","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.ccm.2009.02.007_bib80","doi-asserted-by":"crossref","first-page":"R83","DOI":"10.1186\/ar1954","article-title":"Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study","volume":"8","author":"Vigna-Perez","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ccm.2009.02.007_bib81","unstructured":"Abatacept: (Orencia) [package insert]. Princeton (NJ): Bristol-Myers squibb; 2008."},{"key":"10.1016\/j.ccm.2009.02.007_bib82","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","article-title":"Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition","volume":"353","author":"Genovese","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ccm.2009.02.007_bib83","article-title":"The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-TNF therapy or were directly switched to abatacept: the ARRIVE trial","author":"Schiff","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ccm.2009.02.007_bib84","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1527-3458.2007.00003.x","article-title":"Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases","volume":"13","author":"Stuve","year":"2007","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.ccm.2009.02.007_bib85","unstructured":"Anakinra: (Kineret) [package insert].Thousand Oaks (CA): Amgen; 2008."}],"container-title":["Clinics in Chest Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523109000203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523109000203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:45:07Z","timestamp":1759452307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272523109000203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":85,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["S0272523109000203"],"URL":"https:\/\/doi.org\/10.1016\/j.ccm.2009.02.007","relation":{},"ISSN":["0272-5231"],"issn-type":[{"value":"0272-5231","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Invasive Fungal Infections in the Era of Biologics","name":"articletitle","label":"Article Title"},{"value":"Clinics in Chest Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccm.2009.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}